UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.

August 02, 2024

Vol.50 No.31

Clinical Roundup

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.

August 02, 2024

Vol.50 No.31

In Brief

UCLA researchers awarded $4M to advance immunotherapy treatment for pancreatic cancer

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center were awarded a $4 million grant from NCI to help advance immune-based therapies to improve treatments and outcomes for people diagnosed with pancreatic ductal adenocarcinoma.

July 26, 2024

Vol.50 No.30

Clinical Roundup

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Unexpected role of OTX2 drives aggressive medulloblastoma

Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.

July 19, 2024

Vol.50 No.29

UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

YOU MAY BE INTERESTED IN

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

UCLA researchers awarded $4M to advance immunotherapy treatment for pancreatic cancer

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unexpected role of OTX2 drives aggressive medulloblastoma

Renew today!

Subscriber content

Login